| 83.80 Delayed Data As of Oct 17 |  -0.65 / -0.77%Today’s Change | 66.10 Today|||52-Week Range 87.35 | +9.67% Year-to-Date |
| Better Buy: GlaxoSmithKline vs. Merck Oct 15 / MotleyFool.com - Paid Partner Content | What Happened in the Stock Market Today Sep 30 / MotleyFool.com - Paid Partner Content |
| 3 Dividend-Paying Pharma Stocks to Buy Now Oct 15 / MotleyFool.com - Paid Partner Content | Here’s Why Seattle Genetics Stock Jumped Higher Today Sep 30 / MotleyFool.com - Paid Partner Content |
| Here's Why Seattle Genetics Climbed 17.6% in September Oct 07 / MotleyFool.com - Paid Partner Content | Is GlaxoSmithKline a Buy? Sep 27 / MotleyFool.com - Paid Partner Content |
| Winners and Losers of Europe’s Big Cancer Meeting Oct 02 / MotleyFool.com - Paid Partner Content | How Big Can This $8 Billion-Plus Diabetes Drug Class Get? Sep 26 / MotleyFool.com - Paid Partner Content |
| The Medicines Company Surges on Positive Drug Trial Results Oct 01 / MotleyFool.com - Paid Partner Content | Merck (MRK) Dips More Than Broader Markets: What You Should Know Sep 24 / Zacks.com - Paid Partner Content |
| Previous close | 84.45 |
| Today’s open | 84.42 |
| Day’s range | 83.74 - 84.65 |
| Volume | 6,883,391 |
| Average volume (3 months) | 9,204,205 |
| Market cap | $215.9B |
| Earnings growth (last year) | +165.32% |
| Earnings growth (this year) | +13.16% |
| Earnings growth (next 5 years) | +9.40% |
| Revenue growth (last year) | +6.17% |
| P/E ratio | 23.5 |
| Price/Sales | 4.82 |
| Price/Book | 8.19 |
| Today’s change | Today’s % change | |
|---|---|---|
| PFEPfizer | +0.12 | +0.33% |
| NVSNovartis | +0.23 | +0.26% |
| AZNAstraZeneca | +0.34 | +0.78% |
| SNYSanofi | +0.76 | +1.66% |
| Next reporting date | October 29, 2019 |
| EPS forecast (this quarter) | $1.24 |
| Annual revenue (last year) | $42.4B |
| Annual profit (last year) | $6.2B |
| Net profit margin | 14.65% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Kenilworth, New Jersey |
